Dithiolethiones for cancer chemoprevention: where do we stand?

Yuesheng Zhang¹ and Rex Munday²

¹Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York and ²AgResearch Limited, Ruakura Agricultural Research Center, Hamilton, New Zealand

Abstract

Dithiolethiones are a well-known class of cancer chemopreventive agents; the key mechanism of action of dithiolethiones involves activation of Nrf2 signaling and induction of phase II enzymes. In the past, attention has been focused mainly on 4-methyl-5-pyrazinyl-3H-1,2-dithiole-3-thione (oltipraz), which showed ability as a wide-spectrum inhibitor of chemical carcinogenesis in preclinical models. However, clinical trials of oltipraz have shown questionable efficacy, and at the high doses employed in such studies, significant side effects were observed. Dithiolethiones that are markedly more effective and potent than oltipraz in both induction of phase II enzymes and inhibition of chemical carcinogenesis in preclinical studies have been identified, and these compounds have shown pronounced organ specificity in vivo. Further investigation of these compounds may lead to development of effective and safe agents for cancer prevention in humans. [Mol Cancer Ther 2008;7(11):3470–9]

Introduction

3H-1,2-dithiole-3-thiones (dithiolethiones) are a class of organosulfur compounds of the general structure shown in Fig. 1. The first synthesis of a compound of this class appears to have been by the Italian chemist G.A. Barbaglia who, in 1884, isolated and purified a substance of formula C₅H₆S₃ from the reaction between isovaleraldehyde and sulfur (1). Barbaglia was unable to determine its structure, but from its melting point and the method of synthesis, it would appear likely that this substance was 4,5-dimethyl-3H-1,2-dithiole-3-thione (compound 6; Fig. 1). The parent compound of this class, 3H-1,2-dithiole-3-thione (D3T, compound 1; Fig. 1) was first synthesized in 1948 (2). Many more derivatives were prepared in the late 1940s and 1950s, when considerable interest developed, particularly in France, in the potential industrial and pharmaceutical uses of such compounds (3). Very few achieved commercial success, but two, 5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione (ADT, compound 14; Fig. 1) and 4-methyl-5-pyrazinyl-3H-1,2-dithiole-3-thione (oltipraz, compound 15; Fig. 1), moved on to efficacy trials in humans with regard to therapeutic use. ADT found use as a saliva stimulant (4) and oltipraz was employed in the treatment of schistosomiasis (5, 6).

In the 1980s, interest in this class of compound was greatly stimulated by the work of Bueding’s group at Johns Hopkins University, who reported that oltipraz and ADT, when fed to mice, significantly elevated hepatic levels of glutathione and glutathione S-transferase (GST) and protected against the toxic effects of acetaminophen and carbon tetrachloride (5). Enthusiasm about these and other dithiolethiones was further increased when subsequent studies by Bueding and others showed that the dithiolethiones elevated GST and glutathione as well as other cytoprotective proteins in multiple tissues of both rats and mice in vivo and that oltipraz prevented several carcinogens from causing DNA damage and cancer in animals (7–9). Numerous studies of dithiolethiones have since been carried out. Both oltipraz and ADT have undergone several chemopreventive trials in humans, many new analogues have been synthesized and evaluated, and new chemopreventive mechanisms of dithiolethiones have been identified. Although no dithiolethione has yet been approved for cancer prevention in humans, the wealth of knowledge accumulated on these compounds, particularly oltipraz, offers both guidance and lessons for further research and development of this interesting family of compounds for cancer prevention. In this review, we discuss the preclinical evidence that propelled both oltipraz and ADT to cancer prevention trials in humans, the outcome of these trials, and other dithiolethiones that show promising cancer chemopreventive activity.

Oltipraz

Chemopreventive Efficacy and Safety in Animal Models

Oltipraz is by far the most extensively studied cancer chemopreventive agent among dithiolethiones. It has been
shown to inhibit carcinogenesis in a variety of organs in rodents, including bladder, blood, colon, kidney, liver, lung, pancreas, stomach, and trachea, induced by a large number of carcinogens (Table 1). It has also been reported that oltipraz inhibits cancer development in the mammary gland and skin of rodents (10) and to protect against DNA adduct formation in the aorta of smoke-exposed rats (11). Moreover, oltipraz is effective against many different types of carcinogen (Table 1), some of which are common human carcinogens, such as aflatoxin B1 (AFB1), benzo[a]pyrene, and 2-amino-1-methyl-6-phenylimidazo[4,5]pyridine. Oltipraz is orally active and is effective at dietary levels as low as 200 ppm, which, in the rat, would give a dose of \( \sim 10 \) mg/kg/d. In some animal experiments, oltipraz showed efficacy only when given in the initiation phase (during carcinogen exposure). For example, administration of oltipraz to rats after AFB1 exposure had no effect on liver carcinogenesis (12). In other experiments, however, oltipraz showed efficacy when given either in the initiation phase or post-initiation phase as shown by the inhibition of rat colon carcinogenesis induced by azoxymethane (13). Oral administration of oltipraz also significantly inhibited SVR murine angiosarcoma xenograft growth in nude mice (14), suggesting that oltipraz could also inhibit the growth of advanced cancer.

Chronic toxicity studies in rats, in which oltipraz was administered daily by gavage for 13 weeks at 5 and 50 mg/kg/d and at 10, 30, and 50 mg/kg/d for 52 weeks, revealed liver enlargement at the intermediate and highest dose levels, which was associated with diffuse or centrilobular hepatocytic hypertrophy (15). Slight decreases in erythrocyte count, hematocrit, and hemoglobin level were also recorded, which were associated with an increase in reticulocyte count. Similar effects were seen in dogs given oltipraz at 20 and 100 mg/kg/d for 13 weeks and at 5, 15, and 60 mg/kg/d for 52 weeks (15). The reason for the hematologic changes, whether reflecting hemolysis or hemorrhage, was not established, but the possible role of the disulfide group of oltipraz needs to be considered, because both aliphatic and aromatic disulfides are hemolytic agents in animals (16). Liver enlargement has also been observed in other animal studies on oltipraz (17, 18).

Chemopreventive Activity and Safety in Humans

Several phase I and II cancer chemopreventive trials of oltipraz have been carried out. When human volunteers (6 per group) were given a single oral dose of oltipraz at 125, 250, 500, or 1,000 mg/m², no significant side effects were detected, but the activities of glutamate cysteine synthetase, GST, and NAD(P)H:quinone oxidoreductase 1 (NQO1) in colonic mucosa and NQO1 in peripheral mononuclear cells were significantly increased (19). The induction of gene expression appeared to reach a peak between 2 and 4 days after initiation of treatment and was maximal at a dose of 250 mg/m². Higher doses were not more effective. However, in a follow-up study in which groups of 7 volunteers were given oral oltipraz twice weekly for 12 weeks at either 125 or 250 mg/m², no significant modulation of GST and NQO1 in either colon tissue or blood was recorded (20). Moreover, whereas the low dose was well tolerated by all volunteers, two in the high-dose group required dose reductions due to significant fatigue. In a randomized, placebo-controlled study in China in which oltipraz was administered to volunteers at either 125 mg/d (\( \sim 71 \) mg/m²) or 500 mg/wk (\( \sim 286 \) mg/m²) for 8 weeks (76-80 subjects per arm), a syndrome involving numbness, tingling, and pain in the extremities was associated with oltipraz intake (18.4% and 14.1% of the daily 125 and weekly 500 mg arms, respectively, compared with 2.5% in the placebo arm; ref. 21). These side effects were not new, however, as similar problems were observed more than 10 years earlier in humans taking oltipraz for schistosomiasis treatment (22). Interestingly, in a randomized, placebo-controlled, double-blind phase Ila trial in China, where participants exposed to high levels of dietary AFB1 took oltipraz orally at 125 mg/d or 500 mg/wk for 1 month (80 per arm), similar side effects were not noted (23), suggesting that these side effects occur only after prolonged exposure to this compound. More importantly, the latter study showed that oltipraz at the high-dose regimen inhibited phase I activation (reduced formation of urinary aflatoxin M1) and at the low-dose regimen increased phase II conjugation (increased formation of urinary aflatoxin-mercapturic acid) of aflatoxin, indicating that oltipraz caused potential protective alterations of aflatoxin metabolism in vivo. In contrast, another randomized, double-blind, placebo-controlled trial in smokers, who were enrolled into one of the three arms [200 or 400 mg/wk oral oltipraz or placebo (12-23 subjects per arm) for 12 weeks], found 15% of those receiving oltipraz experienced grade 2/3 toxicity, predominantly gastrointestinal, whereas no significant difference was observed among the trial groups with regard to hydrocarbon-DNA adduct levels in lung epithelial cells, blood, oral lining cells, or bladder lining cells (24). The usefulness of oltipraz in cancer chemoprevention in humans must therefore be called into question, because significant side effects of oltipraz occur in humans at dose levels that show no or questionable chemopreventive efficacy.

Mechanism of Action

Investigation of the cancer chemopreventive activity of oltipraz was launched initially on the basis of its ability to induce cytoprotective enzymes and to elevate glutathione, as mentioned above. Subsequent studies have focused almost exclusively on the extent of modulation of cytoprotection by oltipraz, the underlying mechanism and the extent to which modulation of cytoprotection account for the cancer chemopreventive activity of oltipraz. Oltipraz has been shown to induce phase II enzymes important for detoxification of carcinogens and oxidants, such as NQO1, multiple subunits of GST, glutamate cysteine synthetase, epoxide hydrolase, and UDP-glucuronosyltransferase (25, 26). A major mechanism by which oltipraz induces phase II enzymes is the activation of Nrf2 transcription factor. Nrf2 is normally bound by its repressor Keap1 and targeted for degradation by the ubiquitin-proteosome system. Inducers of phase II...
enzymes, including oltipraz (27, 28), disrupt the Nrf2-Kap1 complex and cause Nrf2 to translocate to the nucleus where it dimerizes with its partners such as Maf, binds to the antioxidant response element (core sequence: 5’T-GACnnnGC-3’) in the promoter region of phase II genes, and stimulates gene transcription (Fig. 2). Knockout of Nrf2 rendered phase II enzymes nonresponsive to oltipraz and caused loss of its cancer chemopreventive efficacy in animal models of both bladder cancer and stomach cancer (27–29). Activation of Nrf2 signaling is therefore critical for inhibition of cancer development. However, it is not clear to what extent the cancer preventive role of Nrf2 depends on induction of phase II enzymes or which specific phase II enzyme is of paramount importance, because Nrf2 also regulates many non-phase II genes (30), and the response of these genes to oltipraz under Nrf2 knockout is probably blocked as well. Modification of critical cysteine residues of Keap1 by inducers and stressors, which frees Nrf2 from Keap1, has been recognized as a key mechanism of Nrf2 activation (31). Although direct reaction of oltipraz with Keap1 cysteine thiols has not yet been shown, dithiolethiones are reactive with thiols (32). Moreover, both oltipraz and D3T have been shown to generate reactive oxygen species in cells (33, 34), which may further contribute to Nrf2 activation, as reactive oxygen species may oxidize the cysteine thiols of Keap1 and/or activate other proteins involved in Nrf2 activation such as protein kinase C (35).

Additional mechanisms may be involved in the regulation of certain phase II enzymes by oltipraz. Human NQO1 promoter is known to contain an AP-1-binding site [TPA response element (core sequence 5’T-GACTCA-3’); ref. 36]. In HT-29 human colon adenocarcinoma cells, oltipraz significantly elevated the mRNA levels of AP-1 factors Jun and Fos as well as that of redox factor-1, which enhances AP-1 binding, and the removal of the AP-1 site in the NQO1 promoter in a reporter construct resulted in 65% loss of the induction by oltipraz (37). Rat UDP-glucuronosyltransferase 1A6 carries a xenobiotic response element (core sequence 5’T-GCGGTG-3’), which was shown to mediate at least partly the induction of this protein by oltipraz in primary rat
hepatocytes (38). Xenobiotic response element is recog-
nized by a heterodimeric complex of aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear trans-
locator. Treatment of human hepatoma HepG2 cells with oltipraz led to increased binding of aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear trans-
locator to the UDP-glucuronosyltransferase 1A6 xenobi-
tic response element (38).

Oltipraz has also been shown to protect against certain carcinogens by inhibiting cytochrome P450s (CYPs or phase I enzymes). Metabolic activation of AFB1 by phase I enzymes is required for its carcinogenic activity (32), and oltipraz was shown to inhibit AFB1 activation by acting as both a competitive and an irreversible inhibitor of both CYP1A2 and CYP3A4 expressed in bacteria (39) and in primary human hepatocytes (40) and of CYP2B in primary rat hepatocytes (41). Rat experiments showed that oltipraz promoted the degradation of CYP2B21 and inhibited CYP1A2-mediated metabolism of AFB1 in vivo (42, 43). Moreover, a single 125 mg dose in humans appeared to reduce CYP1A2 activity by ~75%, as measured by the clearance of caffeine by demethylation, and daily administra-
tion of 125 mg oltipraz for 8 days appeared to result in further inhibition of CYP1A2 (44). However, the effect of oltipraz on CYPs is apparently not always inhibitory. Oltipraz was shown to significantly induce CYP1A2 and CYP3A2 in rat liver in vivo (25, 45), CYP1A in both rat kidney and lung in vivo (42), and CYP1A1 in rat hepatoma H4IIE cells and human colon carcinoma Caco-2 cells in culture (46, 47). Interestingly, the pyrazinyl structure is probably principally, if not entirely, responsible for the inductive effect of oltipraz on CYPs, because the unsubstituted compound, D3T, is largely devoid of such effect (26, 48).

In addition to modulating phase I and II enzymes, one study also reported antiangiogenic activity of oltipraz, showing inhibition of microvessel formation in in vitro, ex vivo, and in vivo assays, which was accompanied by strong inhibition of angiosarcoma xenograft in nude mice (14).

### Pharmacokinetics and Metabolism

14C-labeled oltipraz was administered in a single oral dose to rhesus monkeys (20 mg/kg), Sprague-Dawley rats (50 mg/kg), and CD1 mice (100-250 mg/kg; ref. 49). Only the results in monkeys and rats are discussed below, because the results in mice were compromised due to infection with *Schistosoma mansoni*. Radioactivity levels in plasma reached a maximum at 3 h in both the rat and the monkey, whereas plasma elimination half-lives were 2.5 h in the rat and 3.5 to 7 h in the monkeys; 57% and 52% of the administered dose was eliminated in the urine in 4 days by the monkeys and rats, respectively, and the fecal elimination was 23% and 39% for the monkey and rat. In the blood, unchanged oltipraz accounted for <1% of the radioactivity in the monkeys and 4% to 10% in the rats. The amount of unchanged oltipraz eliminated in the urine in 3 to 4 days was <0.5% to 1%, whereas the amount of unchanged oltipraz eliminated in the feces during the same period was substantially greater: 5% and 13% of the dose in the rat and monkey. Data on plasma levels of oltipraz in animals receiving this substance at dose levels shown to prevent cancer are not presently available, although such information would be of great value in interpreting the results of trials involving oltipraz in humans, because it would permit comparison with the pharmacokinetic profile of oltipraz in humans (50). Plasma concentrations of unchanged oltipraz in humans reached a maximum at 2.2 h after a single oral dose (125-1,000 mg/m²), maximal plasma concentrations (158-671 ng/mL or 0.7-3.0 μmol/L) were proportional to the dose. Plasma elimination half-lives ranged from 9.3 to 22.7 h and were inversely correlated with dose. These plasma concentrations of oltipraz, however, were significantly lower than those required to significantly induce phase II enzymes in cultured cells (10-100 μmol/L; refs. 51–54). Another study showed that urinary concentrations of unchanged oltipraz in humans were similar to those in animals (55). Oltipraz is extensively metabolized; a total of 13 metabolites were detected in the plasma and urine specimens of animals and humans dosed with this

### Table 1. Protection against chemical carcinogenesis by oltipraz in rodents

<table>
<thead>
<tr>
<th>Carcinogen</th>
<th>Species (sex/strain)</th>
<th>Tumor target organ</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-butyl-N-(4-hydroxybutyl) nitrosamine</td>
<td>Mouse (♂, BDF and C57BL/6)</td>
<td>Bladder</td>
<td>27, 81</td>
</tr>
<tr>
<td>2-Amino-1-methyl-6-phenylimidazo[4,5]pyridine</td>
<td>Rat (♂, F344)</td>
<td>Blood/lymphoma</td>
<td>82</td>
</tr>
<tr>
<td>Azoxymethane</td>
<td>Rat (♂, F344 and Sprague-Dawley)</td>
<td>Colon</td>
<td>13, 83–86</td>
</tr>
<tr>
<td>AFB1</td>
<td>Rat (♂, F344)</td>
<td>Kidney</td>
<td>9</td>
</tr>
<tr>
<td>AFB1</td>
<td>Rat (♂, F344)</td>
<td>Liver</td>
<td>26, 87–90</td>
</tr>
<tr>
<td>Benzo[a]pyrene, diethylnitrosamine, uracil mustard</td>
<td>Mouse (♀, ICR/Ha)</td>
<td>Lung</td>
<td>8</td>
</tr>
<tr>
<td>Benzo[a]pyrene</td>
<td>Mouse (♂, A/J)</td>
<td>Lung</td>
<td>91</td>
</tr>
<tr>
<td>N-methyl-N-nitrosourea, diethylnitrosamine</td>
<td>Hamster (♂, Syrian)</td>
<td>Lung</td>
<td>10</td>
</tr>
<tr>
<td>N-nitrosobis(2-oxopropyl) amine</td>
<td>Hamster (♂, Syrian)</td>
<td>Lung</td>
<td>92</td>
</tr>
<tr>
<td>N-nitrosobis(2-oxopropyl) amine</td>
<td>Hamster (♀, Syrian)</td>
<td>Pancreas</td>
<td>93</td>
</tr>
<tr>
<td>Diethylnitrosamine</td>
<td>Hamster (♂, Syrian)</td>
<td>Trachea</td>
<td>94</td>
</tr>
<tr>
<td>N-methyl-N-nitro-N-nitrosoguanidine</td>
<td>Rat (♂, Wistar)</td>
<td>Glandular stomach</td>
<td>95</td>
</tr>
<tr>
<td>Benzo[a]pyrene</td>
<td>Mice (♂, ICR)</td>
<td>Forestomach</td>
<td>96</td>
</tr>
</tbody>
</table>
ADT
Information on ADT is rather limited in comparison with oltipraz. Oral administration of this substance led to induction of phase II enzymes such as GST and NQO1 in multiple tissues in rats and mice; protection against carbon tetrachloride, acetaminophen, and hexachloro-1,3-butadiene toxicities in rodents; inhibition of tumor multiplicity in rats challenged with 7,12-dimethylbenz[a]anthracene; and decreases in both incidence and multiplicity of colon tumors in animals dosed with azoxymethane. In cultured human Jurkat T cells, ADT pretreatment protected cells against oxidative stress-induced cytotoxicity, which was associated with induction of catalase and glutathione reductase and elevation of glutathione levels. Moreover, ADT is reported to be a free radical scavenger and to inhibit lipid peroxidation both in vitro and in vivo. However, a summary of trials with ADT under the National Cancer Institute Chemoprevention Drug Development Program in the United States reported no effect of this substance against several animal models of lung, colon, mammary gland, and bladder cancer. In a randomized phase IIb trial of ADT in smokers with bronchial dysplasia, ADT at 25 mg orally thrice daily for 6 months led to a moderate but statistically significant decrease in the progression of preexisting dysplastic lesions, and the treatment was associated with only minor gastrointestinal symptoms.

Other Dithiolethiones
More recently, many analogues of oltipraz and ADT have been synthesized and evaluated in preclinical models. There were, to our knowledge, no clear features of structure-activity relationship that were used to select these compounds. Rather, compounds were selected based on giving a broad range of representation of structural types. Indeed, studies of these compounds, as described below, did not reveal obvious indicators for high activity. None of these compounds has yet entered clinical trials, but several of them have shown activities that are superior to those of oltipraz and ADT in animal tests. Induction of phase II enzymes remains fundamental to their chemopreventive activity, but their activities have been shown to be associated with significant tissue specificity.

Induction of Phase II Enzymes: Structure-Activity Relationships and Identification of Exceptional Inducers
D3T (compound 1; Fig. 1) was shown to be a potent inducer of phase II enzymes and a powerful inhibitor of AFB1-induced hepatic toxicity and formation of hepatic preneoplastic lesions, whereas its isomer, 1,3-dithiole-2-thione (compound 2; Fig. 1), was largely ineffective, indicating that the 1,2-dithiole structure is essential for chemopreventive activity. In this connection, it is also worth noting that 3H-1,2-dithiole-3-one (compound 3;...
Fig. 1) and oltipraz ketone (compound 16; Fig. 1), both of which retain the 1,2-dithiole structure, whereas the thione group is changed to ketone, were similar to the unchanged compounds in bioactivity in cultured cells (51, 53). The latter finding also led to speculation that these ketone derivatives might be more effective chemopreventive agents than the corresponding dithiolethiones, because oltipraz ketone was shown not to be further metabolized in vitro (55). However, both induction of hepatic phase II enzymes and inhibition of AFB1-induced hepatic DNA damage in rats by either 1,2-dithiole-3-one or oltipraz ketone were weaker than the corresponding dithiolethiones (26).

The inductive activity of many dithiolethiones has been evaluated in cultured cells in vitro. D3T was a more effective inducer of NQO1 than oltipraz in murine hepatoma Hepa1c1c7 cells (68). In a study of 25 dithiolethiones by Egner et al. in Hepa1c1c7 cells (51), 5,6-dihydroxycyclopenta[c]1,2-dithiole-3(4H)-thione (CPDT, compound 17; Fig. 1) was the most potent inducer of NQO1. This compound was 6, 72, and 88 times more potent than D3T, ADT, and oltipraz, respectively, as measured by the concentration of the inducer required to double NQO1 activity in treated cells. It is of note that NQO1 induction in Hepa1c1c7 cells has been a widely used model system for detection of inducers of phase II enzymes (69). Minor structural modifications of CPDT, however, resulted in a marked decrease in inducer activity, as 4,5,6,7-tetrahydrobenzo[c]1,2-dithiole-3-thione (compound 18) and compound 6 (Fig. 1) were 20- and 320-fold weaker than CPDT, respectively. It is also of note that although dithiolethiones induce phase II enzymes in a wide variety of human cell lines in vitro, the response of such cells was not consistent. Indeed, some lines showed no response at all (70, 71). In NBT-II bladder cancer cells, CPDT and D3T showed similar activity in inducing both GST and NQO1, whereas both ADT and oltipraz were significantly weaker inducers (72).

In vivo, most attention has been focused on the effects of dithiolethiones on phase II enzymes in the liver. Kessler et al. (26) showed that D3T when fed to rats in the diet at 0.075% for 1 week increased the activity of hepatic phase II enzymes to a much greater degree than 4-phenyl-3H-1,2-dithiole-3-thione (compound 12) and 5-phenyl-3H-1,2-dithiole-3-thione (compound 13), ADT, and oltipraz. In a subsequent study, among 17 dithiolethiones evaluated in rats for induction of GST and NQO1 in vivo, the magnitude of induction of hepatic activities of GST and NQO1, measured 48 h after a single dose of 1 mmol/kg dithiole-thione, by the following compounds was as follows: 4.4- and 20.8-fold (5-[2-dimethylamino]vinyl-4-methyl-, compound 11; Fig. 1), 2.9- and 10.8-fold (4-methyl-, compound 5; Fig. 1), 3.6- and 9.5-fold (5-methyl-, compound 4; Fig. 1), 3.0- and 10.2-fold (D3T), 2.4- and 7.3-fold (CPDT), and 1.9- and 2.7-fold (oltipraz), respectively (73). Thus, D3T is a more effective inducer than CPDT, which contradicts the results in Hepa1c1c7 or NBT-II cells mentioned above, suggesting that in vitro bioassays do not reliably predict in vivo activity of dithiolethiones. In the latter study, compound 11 showed exceptional inducer activity and was the most effective inducer among all the compounds tested, and oltipraz was one of the weakest inducers. In another study, D3T and CPDT and eight other dithiolethiones (compound 11 was not included) were each administered to rats by oral intubation at 125 μmol/kg once daily for 5 days and tissue activities of GST and NQO1 were measured on the sixth day. Hepatic GST and NQO1 induction levels ranged from 1.2- to 2.0-fold and from 1.6- to 3.5-fold, respectively (72). Although most compounds showed similar inductive activity for GST, the order of inductive activity for NQO1 ranked as follows: 4-chloro-5-methyl-3H-1,2-dithiole-3-thione (compound 7) > compound 13 > compound 12 > compound 18 > D3T > 5-methyl-3H-1,2-dithiole-3-thione (compound 4) > CPDT > compound 6 > oltipraz > ADT (see Fig. 1 for chemical structures). Thus, in this study, both D3T and CPDT showed only modest inductive activities in the liver. Although there is a degree of variation for some of the compounds among the results of the above-mentioned studies, possibly reflecting differences in dosing regimen, it is clear that the two most extensively studied dithiolethiones, oltipraz and ADT, are among the weakest inducers of phase II enzymes in the liver in vivo.

Tissue Specificity in Phase II Enzyme Induction

Although a great deal of data are available on the effects of dithiolethiones on hepatic phase II enzymes, there is much less information on effects in other tissues. In a dose escalation study with D3T, the activities of GST and NQO1 were measured in 13 tissues, including spleen, liver, kidneys, heart, lungs, urinary bladder, glandular stomach, forestomach, duodenum, jejunum, ileum, cecum, and colon/rectum, after rats were dosed orally at 0.98 to 125 μmol/kg once daily for 5 days (74). At the highest dose, D3T caused significant increases in NQO1 and/or GST in all the tissues, with the greatest effects being seen in the kidneys, urinary bladder, forestomach, duodenum, and jejunum. With decreasing dose levels of D3T, the degree of induction and the number of tissues showing significant enzyme induction diminished. However, even at the lowest dose level (0.98 μmol/kg), significant enzyme induction was still detected in the glandular stomach, forestomach, and duodenum, showing that these tissues are particularly sensitive to D3T. In a comparative study involving D3T and nine other dithiolethiones (compounds 4, 6, 7, 12-15, 17, and 18), each of which was administered to rats orally at 125 μmol/kg once daily for 5 days (72), high activity of D3T in many tissues with regard to induction of GST and NQO1 was detected, but different dithiolethiones showed different tissue specificities.

Anticarcinogenic Activity

The anticarcinogenic activities of dithiolethiones other than ADT and oltipraz have been evaluated mainly in
showed induction of two genes known to detoxify dithiolethiones, including oltipraz, in yet another rat study, induced liver preneoplastic lesions in rats among eight and inhibitor of AFB1-induced hepatic injury in rats among also the most effective inducer of hepatic GST and NQO1 once every other day at 13.4 or 40.2 mg/kg (75). D3T was hepatic CYP2C12 in rats gavaged with D3T three times with caution, as a later study showed marked induction of hepatic CYP2C12 in rats gavaged with D3T three times once every other day at 13.4 or 40.2 mg/kg (75). D3T was also the most effective inducer of hepatic GST and NQO1 and inhibitor of AFB1-induced hepatic injury in rats among the nine dithiolethiones evaluated (40.2 mg/kg, three times a week, by gavage), whereas oltipraz was among the weakest agents (73). It is also important to note that the above study also showed a strong positive correlation between in vivo induction of hepatic phase II enzymes and inhibition of AFB1-induced acute hepatotoxicity or formation of GSTP-P foci, highlighting the importance of induction of phase II enzymes in dithiolethione-induced inhibition of carcinogenesis. D3T was again the most effective agent, whereas oltipraz was among the weakest targets (73). In this model, D3T showed an extensive cellular response to D3T.

Other Chemopreventive Activity

In addition to inducing phase II enzymes, D3T has been shown to increase the catalytic subunits of the 26S proteasome, including PSMB5, PSMB6, and PSMB7, in several mouse tissues following oral administration (77) and to stimulate heat shock protein 70 in cultured cells (78). As mentioned above, analysis of hepatic gene expression profiles in D3T-treated wild-type mice and Nrf2-deficient mice showed up-regulation of a large number of genes in Nrf2-dependent manner, including genes for phase II enzymes, chaperones, protein trafficking molecules, proteasome subunits, signaling molecules, and other proteins, showing an extensive cellular response to D3T.

Summary and Future Perspectives

Although the studies of oltipraz and ADT have yielded valuable information on the potential chemopreventive action of dithiolethiones and on the mechanism of such action, recent work suggests that other dithiolethiones may be more promising in preventing cancer. There is a need for more work in several areas to identify and develop dithiolethiones that are ultimately useful for cancer chemoprevention in humans.

Structure-activity relationships among dithiolethiones are by no means clear-cut, and no specific structural feature associated with potent chemopreventive activity has been identified. Progress in this area would facilitate the design and development of dithiolethiones of high activity. Activation of Nrf2 and induction of phase II enzymes has been shown as the fundamental chemopreventive mechanism of dithiolethiones. Hence, identification of structural features that convey potent activation of Nrf2 and induction of phase II enzymes is of particular importance. Further determination of the mechanism whereby these compounds activate Nrf2 and phase II enzymes as well as discovery of novel mechanisms would be of considerable value, especially for identification of biomarkers useful for evaluation of in vivo efficacy of dithiolethiones. Metabolic studies on simple dithiolethiones, such as D3T, are required to establish if it is the parent compound or metabolites that are responsible for the observed activity. Although much information is available on oltipraz in this regard, this compound is not a typical dithiolethione because of the complex metabolic transformations involving the pyrazinyl ring. New information on metabolism of dithiolethiones
may also lead to better understanding of the tissue specificity of dithiolethiones. For example, it has been shown that the high activity of isothiocyanates, another group of well-known chemopreventive agents in the bladder of animals, is due to their metabolism and disposition in the body, leading to the delivery of high concentrations of inducers to the bladder via the urine (79, 80). D3T and CPDT are also highly effective inducers of phase II enzymes in the bladder, but whether this reflects a high urinary excretion of the parent compound or bioactive metabolites is not presently known. Toxicities of oltipraz observed in humans contributed to the difficulty for its further development, but better insight into the tissue specificity of the chemopreventive activity of dithiolethiones may lead to development of agents that are effective in specific tissue(s) and safe for use in humans.

In the final analysis, the most important property of dithiolethiones for cancer chemoprevention is the ability to stimulate the Nrf2-phase II enzymes system. Future work should focus on identifying compounds that are particularly effective in this regard, recognizing the need for whole-animal studies to identify specific tissues in which these substances are particularly effective. In this way, dithiolethiones may be identified that are able to protect against carcinogenesis in human tissues at very low dose levels, and efficacy may be achieved while avoiding the side effects seen in previous studies with dithiolethiones.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

References
26. Kessler TW, Egner PA, Dolan PM, Groopman JD, Roebuck BD. Mechanism of protection against aflatoxin tumorogenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz) and related 1,2-dithiole-3-thiones and 1,2-dithiole-3-ones. Cancer Res 1987;47:4271–7.
33. Velayutham M, Villamena FA, Fishbein JC, Zweier JL. Cancer...


Molecular Cancer Therapeutics

Dithiolethiones for cancer chemoprevention: where do we stand?

Yuesheng Zhang and Rex Munday


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/7/11/3470

Cited articles
This article cites 94 articles, 28 of which you can access for free at:
http://mct.aacrjournals.org/content/7/11/3470.full#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/7/11/3470.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://mct.aacrjournals.org/content/7/11/3470.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.